RESUMO
Aim: in patients with chronic hepatitis B and compensated liver disease, lamivudine reduces s e m HBV-DNA to undetectable levels within 1 to 2 months of treatment. The aim of this study was to evaluate the efficacy of lamivudine in cases with hepatitis B related cirrhosis
Methods: this is a quasi-experimental study on 90 patients with cirrhosis due to hepatitis B. All patients received lamivudine at a dose of 100 mg per day, given orally for 52 weeks. The effect of the drug on liver function, viremia and clinical stage of the disease were assessed
Results: mean age of patients was 53.2 +/- 1.43 years. After 24 weeks and 52 weeks, there were only 28.6% and 26.4% of cases with positive HBV-DNA. Child score had a significant decrease after one year treatment with lamivudine
Conclusion: this study presents a sufficient antiviral effect of lamivudine [Biovudine] in HBV-related cirrhosis patients